Connect with us

Stock Market Sectors

4 Utility Stocks Beating The S&P in September 2018

A. Lawrence

Published

on

Utility Stocks

September is usually a weak month for the stock market. Of the numerous reasons, the most common is that investors take time off during the summer months, which leads to an overall decrease in trading volumes.

Three leading indexes of the stock market, Dow Jones Industrial Average (DJIA), S&P 500 and Nasdaq, have typically performed the worst in that month. Against the backdrop, investors can bet on domestic-focused utility stocks, which are steady performers and payout regular dividends.

4 Utility Stocks That Are Listed By Zacks:

FirstEnergy Corporation (FE) delivered an average positive earnings surprise of 4.74% in the past four quarters. The Zacks Consensus Estimate for 2018 and 2019 earnings moved up 3.0% and 0.4% in the past 60 days, respectively. The company’s expected EPS growth for the next five years is pegged at 6%. FirstEnergy has a dividend yield of 3.79%, higher than S&P 500 Composite’s 1.78%. In the past six months, the company’s shares have gained 13.0%.

IDACORP, Inc. (IDA) delivered an average positive earnings surprise of 10.10% in the past four quarters. The Zacks Consensus Estimate for 2018 and 2019 earnings inched up 2.1% and 0.9% in the past 60 days, respectively. The company’s expected EPS growth for the next five years is pegged at 2.80%. IDACORP has a dividend yield of 2.37%.In the past six months, the company’s shares have gained 19.3%.

DTE Energy Company (DTE) delivered an average positive earnings surprise of 5.69% in the past four quarters. The Zacks Consensus Estimate for 2018 and 2019 earnings moved up 6.7% and 3.6% in the past 60 days, respectively. The company’s expected EPS growth for the next five years is pegged at 5.30%. DTE Energy has a dividend yield of 3.12%. In the past six months, the company’s shares have increased by 11.1%.

Ameren Corporation (AEE)   delivered an average earnings surprise of 7.69% in the past four quarters. The Zacks Consensus Estimate for 2018 and 2019 earnings moved up 5.6% and 0.6% in the past 60 days, respectively. The company’s expected EPS growth for the next five years is pegged at 6.60%. Ameren has a dividend yield of 2.80%. In the past six months, the company’s shares have returned 19.7%.

What To Look For In The Market & With Stocks

A utility is an important piece of meeting basic requirements of households, businesses and the industry. The stability of electricity, water, and natural gas services is not dependent on economic volatility. Utilities supply essentials that have no viable replacement. These are some of the factors that are the primary reasons for the steady performance of these companies

Utility companies continue to reward shareholders and raise their value through regular dividend and share buyback. This makes it a better investment options compared with bonds.  In spite of U.S. administration’s recent move to revive the usage of coal, the utilities in the country are gradually shifting from coal and focusing on other fuel sources, which emit negligible volumes of carbon dioxide.

However, capital-intensive utilities still have their share of weaknesses. Stringent emission rules, weather fluctuation and higher debt loads amid rising interest rates are big concerns for companies like this.

Continue Reading
Click to comment

Biotechnology

Biotech Names To Know In November 2019

A. Lawrence

Published

on

best biotechnology stocks to buy sell

Biotech Stocks Have rallied since The End Of September; What’s Next?

Over the years, the biotech sector has become one of the fastest-growing sectors in the stock market and naturally, investors are keen to get hold of stocks that could follow a similar growth trajectory. However, just because a sector is growing does not mean that an investor can bet on any stock and hope to make decent returns.

In order to choose the right stock, he needs to do a lot of personal research and watch the market closely. Here is a look at three biotech stocks that investors should track closely owing to recent developments.

Sernova Corp’s (TSX:SVA) (OTC:SEOVF)

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

The company’s Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. At the end of October Sernova Corp. (SVA) (SEOVF) detected enduring levels of C-peptide in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes. This C-peptide is a biomarker of transplanted beta-cell insulin production,

Why is this important? According to Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, “Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch.”

Read This Full Press Release Here

Genprex (GNPX)

The first one to put in the watch list is that of Genprex Inc (NASDAQ:GNPX). On Tuesday, the company revealed preclinical data from its study of its product TUSC2 immunogene therapy. The product in question is meant for raising the effectiveness of chemotherapy and anti-PD1 in people suffering from metastatic lung cancers.

The data proved to be positive and that has naturally resulted in a rally in the stock. It is a significant development for Genprex and could potentially help the company in cornering an important portion of the gene therapy market. Hence, it is hardly a surprise that the stock has rallied by as much as 60% after hitting a session’s high of $1.09.

 Can Fite Biopharma (CANF)

The other biotech stock that has made a strong move is the Can Fite Biopharma (NYSE:CANF) stock. The biotech company announced this morning that one of its products, which is meant for the treatment of liver diseases and cancer, has been granted a patent as a sexual dysfunction medicine.

The patents have been granted by the relevant authorities in Canada, Israel, and South Korea. In addition to that, the company has also been awarded patents in Japan, China, United States, Australia, and Hong Kong. It is a highly important development for Can-Fite and it was no surprise when the stock rallied this morning. It has rallied by 3% on Tuesday on the back of the news.

top biotech stocks to watch list

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Entertainment

Is The Entertainment Streaming Market Ready For Its Next Move?

A. Lawrence

Published

on

streaming wars netflix apple hulu disney

New Streaming Options Have Opened A Big Door For Content Providers

As many experts have pointed out, the end of 2019 is going to see the commencement of the ‘streaming wars’ as more and more companies enter the OTT market to challenge the supremacy of Netflix Inc (NASDAQ:NFLX). The launch of the streaming service Disney Plus last week formally launched the streaming wars.

Do Content Providers Stand To Benefit?

According to an article published on Reuters the global video streaming market was valued at $26.27 billion in 2015 and is expected to reach $83.41 billion by 2022 growing at a CAGR of 17.9% from 2015 to 2022. Apple, Disney, Netflix, Amazon, NBC, Hulu & more are all competing within the global video streaming market and they all need the same thing… new & original content. Massive demand may create a huge opportunity for companies like Fearless Films (FERL).

Fearless Films is an independent full-service production company. This is the exact type of company that can benefit from what could become one of the biggest cash grabs in entertainment history and here’s why. You’ve likely heard of the big production houses: Warner Bros, DreamWorks, Red Crown Productions and others who benefited from big deals with streaming companies.

It isn’t just Netflix who’s flexing billions in content budgets, Apple, Amazon, Disney, NBC, Roku – the list goes on. These are huge entertainment distributors who are now fighting for one thing… Where you spend your waking hours streaming entertainment.

Click To Read More On Fearless Films (FERL)

Key Analysis On Streaming Service Providers

Considering the fact that the new service has already garnered 10 million users, it’s fair to say that it is here to say. Considering the fact that Apple has already launched its own service and many other services are going to be launched in the next few months, experts are now wondering whether the streaming space has become too crowded.

The success of Game of Thrones has ushered in an era of unprecedented spending for quality content. The show generated total profit to the tune of $2.2 billion for HBO, which is owned by AT&T. Hence, video streaming companies have also decided to spend jaw-dropping sums on original content. Apple has earmarked $6 billion for original content, while Disney is expected to match that.

streaming cord cutting entertainment stocks

Both companies are trying to create that one show that could turn into a cash cow. On the other hand, Apple is going to price is monthly subscription at $4.99 and Disney is going to charge $6.99 for the same. In such a situation, one can expect Netflix to change tack since its cheapest subscription is worth $12.99.

So, the crowding is quite apparent as mega corporations enter the streaming space. However, the question remains whether the business is going to grow and new subscribers are going to flock in. Studies suggest that it will grow and up until 2024, the streaming market should grow by 18.8% each year. In 2024, the market is going to be worth $687 billion. Hence, it is quite clear that despite the intense competition that is going to come to the streaming space, there is still room for companies to grow and become profitable.

apple tv cord cutting AAPL stock

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $94,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

The Biotech Index Just Hit New Highs; Stocks To Watch

Joe Samuel

Published

on

biotechnology stocks to watch

The Biotech ETF – IBB – Just Made New November Highs, What’s Next?

Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.

However, in order to pick stocks, an individual would need to conduct his own research with regard to different companies. Here is a look at three biotech stocks that should be tracked closely due to recent events.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

What Happened This Week?

top biotech stocks to buy

This week was important for the company as it hit a milestone never met. The company announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

“We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.”

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner

NovaBay Pharmaceuticals (NBY)

The first biotech stock to consider is that of NovaBay Pharmaceuticals, Inc. (NYSE:NBY). The NovaBay stock has been on a tear this morning owing to an important product announcement from the company. The company issued a press release this morning in which it revealed that its product NovaSight has been launched on Amazon.

The product in question is a mineral supplement and a daily vitamin that is meant for the eyes. After the announcement was made, the stock rose by as much as 26.50% in Monday’s trade and it remains one of the stocks to watch on the market today. The announcement is a significant one and could have far-reaching implications for NovaBay.

REPORT: 1 Biotech Stock is Positioning Itself for Success

BioCryst Pharmaceuticals (BCRX)

Another biotech stock that has been in the middle of a highly impressive rally in recent sessions is that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The stock has gained over the course of the past three trading sessions and has generated gains of as much as 28% so far.

In a new development, the company completed a capital raise by offering its equity and managed to raise as much as $55 million. This prompted Bank of America analysts Tazeen Ahmad to upgrade the stock from neutral to buy. The capital raise and the upgrade possibly resulted in the remarkable rally in the BioCryst stock in recent days.

REPORT: 1 Biotech Stock is Positioning Itself for Success

make money with penny stocks biotech

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com